• Explore /
  • Poster
  • / Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

Abstract Video & Slides Poster

Authors

Andrew Zelenetz

Andrew David Zelenetz

Memorial Sloan Kettering Cancer Center, New York, NY

Andrew David Zelenetz , Wojciech Jurczak , Vincent Ribrag , Kim Linton , Graham P. Collins , Javier López-Jiménez , Nishitha Reddy , Andrea Mengarelli , Tycel Jovelle Phillips , Gerardo Musuraca , Oonagh Sheehy , Joanne Li , Weiming Xu , Michel Meyer Azoulay , Richard Ghalie , Pier Luigi Zinzani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03768505

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7511)

DOI

10.1200/JCO.2022.40.16_suppl.7511

Abstract #

7511

Poster Bd #

165

Abstract Disclosures

Similar Posters

First Author: Martin H. Dreyling

First Author: Pier Luigi Zinzani

First Author: Ian W. Flinn

First Author: Christopher Flowers